STAT1 is mediating the antiproliferative activity of therapeutic IFNα [38], and CML cells lacking STAT1 expression have shown to be resistant to IFNα treatment [39]. The gene discussed is STAT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.